FBC
AZN icon

Fairfield, Bush & Co’s AstraZeneca AZN Stock Holding History

Fairfield, Bush & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-175
Closed -$23.6K – 135
2023
Q4 		$23.6K Buy
+175
New +$22.8K 0.01% 239
2023
Q3 		– Sell
-175
Closed -$25.1K – 130
2023
Q2 		$25.1K Buy
+175
New +$25.7K 0.01% 257
2022
Q3 		– Sell
-213
Closed -$28K – 137
2022
Q2 		$28K Buy
+213
New +$27.9K 0.02% 230

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fairfield, Bush & Co's AZN Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 175 shares — an estimated $23.6K sold.

Fairfield, Bush & Co first reported a position in AZN in Q2 2022 and held it in 3 quarters. The position peaked at $28K in Q2 2022. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 175 AstraZeneca shares in Q1 2024, an estimated $23.6K.
  • Fairfield, Bush & Co first reported a position in AstraZeneca in Q2 2022 and held it in 3 quarters.
  • Fairfield, Bush & Co's AstraZeneca position peaked at $28K in Q2 2022.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.